Atossa Therapeutics Raises $4.5 Million to Support Oncology Clinical Development Efforts
- Atossa Therapeutics raises approximately $4.5 million from a registered direct offering to support clinical efforts in oncology.
- The offering includes 1,363,637 shares and warrants that could raise an additional $12 million if fully exercised.
- Funds will be used for clinical development and working capital to address unmet medical needs.
Atossa Therapeutics (ATOS) successfully finalizes a registered direct offering, generating approximately $4.5 million. This funding is crucial as the company progresses its clinical efforts aimed at addressing significant unmet medical needs in oncology.
New Funding Aims for Clinical Development
The offering involves 1,363,637 shares along with Series A and Series B warrants. If all warrants are exercised, Atossa could potentially receive an additional $12 million, enhancing its financial position. The Series A warrants have a lifespan of 5.5 years, while the Series B warrants are valid for 2 years. Rodman & Renshaw LLC serves as the exclusive placement agent for this transaction.
Commitment to Innovative Oncology Therapies
Atossa intends to utilize the net proceeds primarily for clinical development and working capital. This focus aligns with its ongoing commitment to providing innovative therapies in oncology. The company’s lead product candidate, (Z)-endoxifen, is currently undergoing various stages of clinical development, exemplifying Atossa’s drive to meet critical health needs.
Forward-Looking Statements Provided
Atossa emphasizes the variability in potential proceeds from the offering based on the exercise of the warrants. Recent updates about these developments are available on the SEC website and Atossa’s corporate site, keeping stakeholders informed and engaged.
Related Cashu News
Ionis Pharmaceuticals Highlights Long-Term Efficacy and Safety of Olezarsen for Hypertriglyceridemia
Ionis Pharmaceuticals (Ticker: IONS) shares promising long-term data on its RNA therapy olezarsen, designed to treat severe hypertriglyceridemia. The recent findings from an ongoing extension study hi…
Voyager Therapeutics: Promising Growth in Gene Therapy for Neurological Diseases Amid Financial Challenges
Voyager Therapeutics positions itself as a growth option in the gene therapy sector, particularly in the treatment of neurological diseases. The company's recent performance reveals critical insights…
Qiagen NV Advances QIAcuity Digital PCR Ecosystem with Enhanced Tools and Automation.
Qiagen NV (Ticker: QGEN) enhances its QIAcuity digital PCR ecosystem with significant advancements recently announced. The new tools expand gene expression capabilities, allow for improved multiplexin…
Regenxbio Advances NAVSUNLI Gene Therapy for Hunter Syndrome with FDA Support and Upcoming BLA Resubmission
Regenxbio (Ticker: RGNX) is making significant strides in the field of gene therapy with its recent alignment with the U.S. Food and Drug Administration (FDA) concerning the potential accelerated appr…